Introduction
Cancer-induced bone pain (CIBP) is a clinical problem with up to 85% of patients suffering from severe hyperalgesia and tactile allodynia, 1 and it can severely compromise the quality of life. 2 Currently, there is no effective medicine or method to treat CIBP because molecular mechanisms responsible for the induction and maintenance of bone cancer pain are not fully understood. Recent evidence has demonstrated that glial cells, including microglia in the spinal cord, play important roles in molecular mechanisms of cancer pain. 3, 4 Activation of glial cells is considered to trigger the production and release of proinflammatory cytokines (interleukin-1β [IL-1β], interleukin-6 [IL -6] , and tumor necrosis factor-α [TNF-α]) that contribute to pain hypersensitivity.
antiplatelet therapy and neuropathic pain. Blocking P2Y 12 R has been suggested as a possible treatment for neuropathic pain and inhibition of platelet function. [7] [8] [9] Recently, it has been reported that the activation of p38 mitogen-activated protein kinase (p38MAPK) plays an important role in proinflammatory cytokine production and the progression of neuropathic pain. More recent studies have shown that spontaneous pain and tactile allodynia in female rats with tibial tumors are associated with increased production of phosphorylated-p38MAPK (p-p38MAPK) and proinflammatory cytokines (IL-1β and TNF-α) in the spinal cord of CIBP. 10 In light of the importance of this receptor in neuropathic pain and platelet activation, we asked whether microglial P2Y 12 R plays a similar role in CIBP. Therefore, the purposes of this study are 1) to investigate whether P2Y 12 R is involved in the establishment of rat CIBP model by inoculating Walker 256 breast cancer cells in the tibia and 2) to examine the effect of P2Y 12 R antagonist on spinal neuroimmune activity in a CIBP model.
Methods Animals
All treatment protocols were strictly adhered to the guidelines of the International Society for Pain Research program on animal use. The study was approved by the Jiaxing University's Institutional Animal Care and Use Committee (IACUC).
Unmated female Sprague Dawley rats (200-250 g) used in the study were provided by Zhejiang Academy of Medical Sciences (Hangzhou, People's Republic of China). All animals were housed in the animal facility of our hospital under standard conditions with a 12 h light/dark cycle, a constant room temperature of 22-24°C, and humidity of 40-60%. Food and water were available ad libitum. Behavioral studies were conducted in a quiet room between 8 am and 8 pm.
Bone cancer model
Under anesthesia with chloral hydrate (400 mg/kg, intraperitoneal), the left leg of the rat was shaved and disinfected with iodine. The tibia was pierced using a 25 G needle, and then 5 µL (2´10 7 /mL) suspension of Walker 256 tumor cells was injected slowly into the bone cavity with a 10 µL microsyringe. The rats were placed on a hot pad until they returned to normal. The control group did the same surgical treatment as the cancer group, but the same amount of Hank's solution was injected into the left tibia metaphysic. The normal group (rats) did not receive any treatments.
Intrathecal catheterization
Intrathecal catheterization between L4 and L5 was done immediately after inoculating tumor cells by inserting a PE-10 microtube into the vertebral space as previously described. 11 Briefly, an intrathecal catheter (PE-10) filled with sterile saline (~10 µL) was inserted into the intervertebral gap between L4 and L5. After 1 day recovery, 2% lidocaine (20 µL) was injected intrathecally in rats without impaired motor performance. If the rats showed paralysis of the lower limbs within 30 s, it indicated the successful insertion of the catheter. Rats with significant local infection, abnormal activity, paralysis, and catheter loss were excluded. MRS2395 or 5% dimethylsulfoxide (DMSO) (v/v, in normal saline) (15 µL) was injected from days 9 to 12 (daily administration) by Hamilton syringe.
Mechanical allodynia (Von Frey test)
The rats were placed in a plastic box (20 cm ×20 cm ×30 cm) on a metal plate and allowed to acclimate to the environment for 30 min. The "paw withdrawal thresholds" (PWTs), the minimum force to evoke a withdrawal response and the tactile threshold, were measured on hind paws ipsilateral to surgery three times at 3 min intervals by electrical mechanical analgesia tester before and every 10 min (last for 70 min) after the application of MRS2395 (400 pmol/µL, 15 µL, intrathecal [i.t.]) or DMSO (5%, 15 µL, i.t.) on day 9 postinoculation and, then, once a day from days 9 to 12. The average was considered as a value to mechanical stimuli. The investigator was unaware to the test group. All the PWTs as raw data were given in grams.
Immunohistochemistry
On day 12 postinoculation, after Von Frey testing, the rats were deeply anesthetized with 4% chloral hydrate (600 mg/kg), and then the aorta was warmed with warm saline, followed by injection of cold 4% paraformaldehyde (pH 7.2-7.4). After perfusion, the rat L4-L6 spinal cord segments were removed and fixed in the same fixative for 2-4 h, after which they were soaked in 30% sucrose solution. Frozen sections with a thickness of 30 mm were cut using a microtome (Leica CM1900), and five nonadjacent sections were randomly selected for immunohistochemical staining. Sections were incubated in 3% H 2 O 2 for 10 min and then with primary antibodies for the antiionized calcium-binding adapter molecule 1 (Iba-1) (1:100, goat; Abcam, Cambridge, UK) and p-p38MAPK (1:500, rabbit; Cell Signaling Technology, Denver, CO, USA) overnight at 4°C. Then, the sections were washed three times with phosphate buffer saline (PBS) and incubated with an antigoat or antirabbit second antibody for 30 min at room temperature.
The primary antibody was omitted and incubated directly with the secondary antibody, resulting in negative staining of Iba-1 and p-p38MAPK. The color development was carried out with 0.06% diaminobenzidine. Under a microscope, 0.01 M PBS solution was used to terminate the color reaction. The sections were placed on a glass slide, dried, dehydrated, cleared, and finally covered with cover slips. The sections were observed under fluorescence microscopy (C7070wz; Olympus Corporation, Tokyo, Japan), and images were captured. Five regions were randomly selected from the fixed size (an area of 200 µm ×300 µm) of the spinal dorsal horn (I-IV layers) in each image and evaluated using Image-Pro Plus. The average number of Iba-1-immunoreactive (Iba-1-IR) and p-p38MAPK-positive cells was determined (n=4). All results were expressed as mean ± SD.
Western blot analysis
Rats were first deeply anesthetized and decapitated, and L4-L6 segments of spinal dorsal horn were cut out quickly and disposed with protease and phosphatase to make it homogenized. The homogenate was centrifuged at 13,000× g at 4°C for 10 min. The supernatant was used for Western blot analyses. Protein concentration in the homogenate was measured using the bicinchoninic acid (BCA) kit and used to calculate volume for equal protein loading. After transferring, the polyvinylidene fluoride membranes were exposed to specific antibodies against P2Y 12 R (1:500, rabbit antimouse P2Y 12 R antibody; Merck & Co., Kenilworth, NJ, USA), Iba-1 (1:1000, rabbit antimouse Iba-1 antibody; Merck & Co.), p-p38 MAPK (1:1000, rabbit anti-mouse p-p38 MAPK antibody; Merck & Co.), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (1:20,000, rabbit antimouse GAPDH antibody; Sigma-Aldrich, St Louis, MO, USA) overnight at 4°C. After extensive washing with tris buffered saline with Tween ® , the suspension was incubated with a dilution of horseradish peroxidase labeled goat antirabbit immunoglobulin G antibody with a ratio of 1:5000 for 1 h at room temperature. Following extensive washing, the signal was detected using Western Lightning ECL and measured by the optical densitometry on Image-Pro Plus6.0 using β-actin as a control.
Cytokine analysis
To determine IL-1β, IL-6, and TNF-α levels, the L4-L6 segments of the spinal cord were collected 4 h after intrathecal injection on day 12 postinoculation. The tissues were washed twice with PBS and cut into pieces with sterile scissors. After being milled, the tissues were digested with 1% collagenase for 25 min at 37°C. The supernatant was collected after centrifugation (12,000× g, 10 min). The samples were then boiled at 95°C for 10 min before being processed for Western blot analysis. Primary antibodies anti-IL-1β, anti-IL-6, and anti-TNF-α (rabbit; Abcam), together with the antirabbit secondary antibody, were used to detect the cytokines produced in these tissues.
Statistical analysis
All results are presented as mean ± SD. Statistical tests were performed using SPSS (Version 11.5). The changes of the PWTs and the immunohistochemistry staining of Iba-1 and p-p38MAPK in all groups were analyzed by two-way analysis of variance (ANOVA) followed by least significant difference (LSD) (when homogeneity of variance) or Tamhane's T2 (when heterogeneity of variance) post hoc test. Unpaired T-test was used for blot analysis. The production of IL-6, IL-1β, or TNF-α cytokines was analyzed by one-way ANOVA and then compared by LSD post hoc test. Figures were prepared using Adobe Illustrator CS (Version 11.0; Adobe Systems, San Jose, CA, USA). For all experiments, P<0.05 indicates statistically significant difference.
Results

Effects of intrathecal injection of MRS2395 on mechanical allodynia in CIBP
To examine the effects of MRS2395 on bone cancer-induced pain behaviors, vehicle (DMSO) or MRS2395 was intrathecally administered in the cancer or sham groups. As shown in Figure  1A , the PWTs did not change in the sham + DMSO and sham + 2,2-Dimethyl-propionic acid 3-(2-chloro-6-methylaminopurin-9-yl)-2-(2,2-dimethyl-propionyloxymethyl)-propyl ester (MRS) groups (P>0.05, n=8/group). In contrast, the PWTs were significantly decreased in the cancer + DMSO group on day 9 postinoculation (P<0.01, n=8/group; Figure 1A Figure 1A ). The results show that the use of MRS2395 can reduce the mechanical allodynia. Thresholds of cancer + DMSO group and cancer + MRS group were obviously reduced than that of sham + DMSO group on days 9-12 postinoculation (P<0.01); compared to thresholds of cancer + DMSO group, thresholds of cancer + MRS group were increased obviously at 30 min post-MRS2395 intrathecal injection on day 9 postinoculation (P<0.01). However, the thresholds of cancer + MRS group had a slight enhancement during days 10-12 postinoculation that did not reach statistical significance (P>0.05, Figure 1B ).
CIBP increases P2Y 12 R expressions in spinal dorsal horn
To study the effects of CIBP on P2Y 12 R expression, we measured the relative densitometry of immunoblots of P2Y 12 
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Liu et al protein in the L4-L6 spinal cord from normal groups, sham groups, and cancer groups. As shown in Figure 2A and B, the expression of P2Y 12 R in the L4-L6 spinal cord was increased in bone cancer rats (n=4, # P<0.05 vs normal groups, *P<0.05 vs sham groups). These data suggested that CIBP led to a significant increase in P2Y 12 R expression in the L4-L6 spinal cord.
Effects of intrathecal injection of MRS2395 on the activation of spinal microglia induced by bone cancer
To examine whether microglia activation was associated with P2Y 12 R, we analyzed by Western blot (Figure 3 ) and immunohistochemistry ( Figure 3A and B). The expression of the microglial markers was examined in the L4-L6 spinal cord of sham rats and bone cancer rats that received administration of the P2Y 12 R antagonist MRS2395 or DMSO. Western blot analysis revealed that the level of Iba-1 was upregulated in cancer group and partially inhibited by MRS2395 (P<0.05) ( Figure 3C and D) . The morphology of microglia in the sham + DMSO and sham + MRS2395 groups showed that they were nonactivated with small cell bodies and more ramifications ( Figure 3A ).
Microglia were significantly activated in the cancer + DMSO group, exhibiting the characteristics of swollen cell bodies and retracted processes ( Figure 3A ). This activation was obviously suppressed by MRS2395 ( Figure 3A) . The number of Iba-1-positive cells (37.35±3.34) in the cancer + MRS2395 group was significantly lower than that in the The PWTs on the ipsilateral side of bone cancer were partly increased after intrathecal injection of MRS2395 (400 pmol/µL, 15 µL, once daily) from days 9 to 12 postinoculation, but there was no significance between the cancer + DMSO group and the cancer + MRS group. Eight rats were used in each group. Abbreviations: I.t., intrathecal; PWTs, paw withdrawal thresholds; DMSO, dimethylsulfoxide; MRS, 2,2-Dimethyl-propionic acid 3-(2-chloro-6-methylaminopurin-9-yl)-2-(2,2-dimethyl-propionyloxymethyl)-propyl ester. Figure 3B ), indicating that the activation of microglia was partially inhibited by MRS2395.
Effects of intrathecal injection of MRS2395 on p-p38MAPK expression in the spinal cord induced by bone cancer
It has been reported that nerve injury can activate the cascade of p38MAPK and the activation of p38MAPK in microglial cells in the spinal cord can cause neuropathic pain. To verify whether p38MAPK phosphorylation was regulated by P2Y 12 R in CIBP, the expression of p-p38MAPK protein in dorsal horn was examined by Western blot and immunohistochemistry using anti-p-p38MAPK antibody. Western blot analysis revealed that the level of p-p38MAPK was increased in the cancer group and partially suppressed by MRS2395 (P<0.05) (Figure 4 ).
In addition, we found that immunoreactive cells migrate into the dorsal horn of the spinal cord, especially in the superficial dorsal horn. The morphology of p-p38MAPK-positive cells in sham groups showed that the cells were more inactivated with less numbers and smaller cell bodies, while they were significantly activated in the cancer + DMSO group with more numbers and swollen cell bodies ( Figure 4A ). Furthermore, this activation was significantly inhibited by MRS2395 ( Figure 4A ). As shown in Figure 4B , the number of the p-p38MAPK-positive cells was significantly upregulated in the cancer group and partially suppressed by MRS2395 (P<0.01; n=4/group). In order to fully reveal the impacts of MRS2395 intervention on spinal nociceptive responses, the expression of proinflammatory cytokines in the spinal L4-L6 fragments was observed by Western blot. An inhibitor of p38MAPK, SB-203580, has been included in this study. It showed a significant upregulation of proinflammatory cytokines in the cancer + DMSO group, ie, IL-1β (P<0.001, n=4; Figure 5A ), IL-6 (P<0.001, n=4; Figure 5B ), and TNF-α (P<0.05, n=4; Figure 5C ), compared to that in the sham groups. It also showed a significant decrease in IL-1β (P<0.01, n=4; Figure 5A ) and IL-6 (P<0.001, n=4; Figure 5B ) production in the MRS2395-treated cancer group and SB-203580-treated cancer group, but not TNF-α, compared to that in the DMSOtreated bone cancer pain rats.
Discussion
In this study, we provide evidence for the first time that the activation of P2Y 12 R in spinal microglial plays an important role in the development and progression of CIBP, using immunohistochemical, pharmacological, and Western blot approaches. The new findings are as follows: 1) CIBP induced an increase in the expression of P2Y 12 R in spinal cord; 2) the intrathecal infusion of the P2Y 12 R antagonist MRS2395 suppressed the activation of microglia in CIBP; 3) the inhibition of P2Y 12 R decreased the expression of proinflammatory cytokines; and 4) the intrathecal infusion of the P2Y 12 R antagonist MRS2395 partly attenuated mechanical allodynia in CIBP. The P2Y 12 R was initially found expressed on platelets and has a formal name "P2ADP receptor" because it is activated by ADP. 12 Later, this receptor was cloned from the rat platelet cDNA library and was renamed "P2Y 12 R".
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P2Y 12 R has been reported to be expressed constitutively in spinal microglia. 7, 14, 15 This study extended these findings by showing the dynamic upregulation of spinal microglia in CIBP. In addition, intrathecal administration of MRS2395 (an inhibitor of P2Y 12 R) inhibited the microglial activation. The main reason for the decreased number of microglia in the ipsilateral spinal cord was considered to result from the inhibition of P2Y 12 R. The increased expression of spinal microglia in the immunohistochemistry for Iba-1 suggested that P2Y 12 R was simultaneously expressed in CIBP by our data. P2Y 12 R-mediated microglial functions (eg, process movement, chemotaxis, and morphological changes) were considered to be indispensable to the development of mechanical allodynia in CIBP. Mice with P2Y 12 deficiency (P2Y 12 -/-) displayed impaired tactile allodynia after nerve injury without any change in basal mechanical sensitivity. These results, along with P2Y 12 R localization that highly limits to microglia, suggested that activation of P2Y 12 R in the spinal cord was an important cause of allodynia in CIBP.
Consulting a rat model of bone cancer pain reported by Medhurst et al, 16, 17 intrathecal administration of MRS2395 alleviates pain hypersensitive behaviors. The PWTs started to increase from 20 min, peaked at 30 min, and lasted for 40 min following intrathecal injection of MRS2395 on day 9 postinoculation, indicating a transient inhibitory action. Kobayashi et al 7 reported that the time course of P2Y 12 R upregulation in neuropathic pain was different for CIBP in microglia; it peaked at day 3 after nerve injury and returned to normal after 30 days, suggesting that the expression of nucleotides receptors in microglia cells was regulated by different regulatory mechanisms. The mechanism suggested that cancer pain was composed of nerve injury-induced neuropathic pain and proinflammation pain. 18 An absence of microglia activation was a characteristic of the spinal cord central sensitization in mouse models of bone cancer pain. 19, 20 Furthermore, it has been demonstrated that microglia are the early responders to glial cells, and then followed by the activation of astrocytes, which in turn keep such long-term pathological states maintained as persistent pain. 21 Activation of spinal microglia and astrocytes has been demonstrated by several teams to contribute significantly to the maintenance and development of neuropathic pain and inflammatory. 22 It is suggested here that the activation of microglia and astrocyte extensively related to long-term hyperalgesia. This study provides more convincing evidence that spinal microglia have a strong association with the development of cancer pain. It is difficult to control bone cancer pain because pathological reconstruction has emerged from CNS, namely central sensitization. To suppress the formation of spinal sensitization at early station, it may be feasible to restrain the activation of microglia. Most importantly, the inhibitory effect of MRS2395 on bone cancer cell-induced pain hypersensitivity in rats makes the drug a promising candidate for clinical application.
We hypothesized that the alleviation of pain mediated by MRS2395 in bone cancer pain may use a complex downstream signaling pathway, namely p38MAPK pathway. Now studies have shown that the activation of p38MAPK induced by bone cancer can be significantly inhibited by intrathecal injection of MRS2395, which was consistent with the previous reports. As one of the most important members of the MAPK family, p38 was also found activated in bone cancer pain models, [23] [24] [25] in addition to inflammatory pain and neuropathic pain models. [26] [27] [28] Many works have shown that p38 played important roles in the development of bone painrelated and bone cancer-related processes. For example, p38 has been found positively regulating the osteoclastic activity and plays an important role in the metastasis and growth of bone cancer cells. 29 Recently, Cottrell et al demonstrated that p38 inhibition was a therapeutic strategy for managing fracture pain. 30 In addition, P2Y 12 R antagonist MRS2395 and antisense knockdown of P2Y 12 R expression suppressed the phosphorylation of p38MAPK in spinal microglia after partial sciatic nerve ligation. 7 In contrast, it has been demonstrated that the P2X 7 purinoceptor and p38MAPK, both selectively expressed by activated spinal microglia, may also be required to maintain pain behavior in CIBP. 31 The activation of spinal microglia has been demonstrated in bone cancer pain. Additionally, it may contribute to the hypersensitivity by releasing IL-1β and TNF-α. 5, 10, 20 A recent study suggested important roles of proinflammatory cytokines for tumor growth and bone cancer-associated pain. 5 The increased proinflammatory cytokine production by glial cells has been now considered as an important marker for the identification of glial activation in chronic pain. 32 In this study, the expression of IL-1β and IL-6 was significantly inhibited in the cancer group at the 12th day after intrathecal injection of MRS2395, with a mild increase in TNF-α. Therefore, peripheral inflammation has profound effects on the nervous system, and cytokines seem to be major players for such effects. The expression of inflammatory cytokines is dissimilar, reflecting the different mechanism in the pathogenesis of bone cancer pain. IL-1β is secreted by mononuclear cells, skin cells, fibroblasts, endothelial cells, and so on, playing a very important role in the local immunity. IL-6 is the main mediator in infection and tissue damage. TNF-α is early released by mononuclear macrophages under stress, initiating other cytokines and involving in immune adjustment, fever, and inflammation. It needs further study on their specific interactions in bone cancer pain. Thus, the inhibition of proinflammatory cytokine expression by MRS2395 may be at least partially attributed to the antiallodynic effect of MRS2395 in bone cancer pain. In the behavioral study, allodynia induced by bone cancer was significantly inhibited after MRS2395 intervention. Therefore, we speculate that the P2Y 12 R might correlate with bone cancer-induced allodynia. It has been proposed that the descending pain facilitation can partially underlie pain hypersensitivity. This study demonstrates that intrathecal injection of MRS2395 can reverse this facilitation by inhibiting microglial activation without disrupting pain memory. This is significantly different from the analgesic effects of morphine in neurons. 
Conclusion
The P2Y 12 R can induce the activation of spinal microglia in CIBP through p38MAPK signaling pathway. Consequently, the activation of spinal microglia p38MAPK signaling pathway in CIBP may lead to increased production of proinflammatory cytokines or other effectors into the nociceptive network, resulting in the manifestation of cancer pain behaviors. Taken together, P2Y 12 R plays a critical role in spinal microglia activation in CIBP and represents a potential therapeutic target for cancer pain management.
